Welcome to our dedicated page for Foghorn Therapeutics news (Ticker: FHTX), a resource for investors and traders seeking the latest updates and insights on Foghorn Therapeutics stock.
Foghorn Therapeutics Inc. (Nasdaq: FHTX) generates news as a clinical-stage biotechnology company focused on oncology medicines that target genetically determined dependencies within the chromatin regulatory system. Its updates frequently highlight progress from the Gene Traffic Control® platform, which systematically identifies and validates chromatin-based targets for small-molecule inhibitors and protein degraders.
News about FHTX often centers on its lead clinical candidate FHD-909 (LY4050784), a first-in-class oral SMARCA2 selective inhibitor being evaluated in a Phase 1 multi-center dose-escalation trial for SMARCA4-mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population. Press releases describe preclinical data, trial enrollment status, and combination strategies with standard-of-care chemotherapies, pembrolizumab, and KRAS inhibitors in NSCLC models.
Investors following FHTX can also expect regular announcements on Foghorn’s selective degrader programs. These include a selective CBP degrader with potential in EP300-mutant cancers and ER+ breast cancer, a selective EP300 degrader for hematologic malignancies such as multiple myeloma and diffuse large B-cell lymphoma, and a selective ARID1B degrader for ARID1A-mutated solid tumors. Company communications summarize preclinical efficacy, tolerability, and formulation advances, as well as milestones such as progression into toxicology or IND-enabling studies.
Another recurring theme in Foghorn’s news flow is corporate and financial activity. Releases discuss collaboration revenue from its strategic partnership with Lilly, cash and marketable securities levels, and equity financings conducted under a shelf registration statement on Form S-3, including a registered direct financing that raised approximately $50 million in gross proceeds. Updates on leadership changes in the finance function and participation in healthcare and investor conferences also appear in FHTX news.
By monitoring this news page, readers can review company-issued information on trial progress, preclinical data, financing transactions, collaborations, and corporate developments that shape the ongoing story of Foghorn Therapeutics’ chromatin-focused oncology pipeline.
Foghorn Therapeutics (Nasdaq: FHTX) announces participation in the William Blair Biotech Focus Conference 2021 with CEO Adrian Gottschalk on July 15 at 9:00 a.m. ET. The conference will focus on next-generation small molecules in oncology. A live webcast of the panel can be accessed through the company’s website under the ‘Events & Presentations’ section. Foghorn is dedicated to developing a novel class of medicines targeting genetically determined dependencies in the chromatin regulatory system, with ongoing projects in oncology.
Foghorn Therapeutics Inc. (Nasdaq: FHTX) will host a research and development webinar on June 15, 2021, from 9:00 AM to 11:00 AM EDT. Key presentations will be made by management and experts from notable institutions, including Howard A. Burris III and Eytan Stein. The event will cover the significance of the chromatin regulatory system in gene expression and its application in precision oncology, featuring Foghorn's Gene Traffic Control platform. A live Q&A session will follow the presentations. Registration is available online.
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced that CEO Adrian Gottschalk will present at two upcoming investor conferences. The Jefferies Virtual Healthcare Conference is scheduled for June 1, 2021, at 10:00 am ET, featuring a presentation and one-on-one meetings. The Goldman Sachs 42nd Annual Healthcare Conference will take place on June 8, 2021, at 8:00 am ET, including a fireside chat and one-on-one meetings. Interested investors can access the live webcasts through the company’s website under the “Events & Presentations” section.
Foghorn Therapeutics (Nasdaq: FHTX) announced the first patient has been dosed in a first-in-human clinical trial of FHD-286, targeting metastatic uveal melanoma (mUM) and relapsed/refractory acute myelogenous leukemia (AML). This marks a significant milestone as FHD-286 is the first clinical candidate from Foghorn's diverse pipeline, designed to inhibit the chromatin regulatory system. Both trials are open-label and focus on safety and efficacy, highlighting Foghorn's innovative approach to treating cancers with limited options.
Foghorn Therapeutics (Nasdaq: FHTX) received IND clearance for FHD-609, a targeted protein degrader for synovial sarcoma. This marks a significant milestone alongside advancement in their therapeutic pipeline aimed at the chromatin regulatory system. FHD-609 is Foghorn's second drug to enter clinical trials, with initial data expected in early 2022. The company also received IND clearance for FHD-286, targeting relapsed AML and metastatic uveal melanoma. Financially, Foghorn reported cash and equivalents of $160.9 million as of March 31, 2021, down from $185.8 million at year-end 2020.
Foghorn Therapeutics (FHTX) announced the appointment of Ian Smith to its Board of Directors, effective April 27, 2021. Smith, a seasoned biotechnology leader, has been advising Foghorn since 2020 on business development and financing strategies. CEO Adrian Gottschalk expressed optimism over Smith's experience in capital formation and business growth, which is expected to enhance the company’s focus on chromatin regulatory systems. Smith brings a wealth of experience from positions at Viacyte and Vertex Pharmaceuticals, which may contribute to Foghorn's potential therapeutic breakthroughs in oncology.
Foghorn Therapeutics Inc. (Nasdaq: FHTX) issued a corporate update, revealing that the company has received IND clearances for its therapeutic candidate FHD-286. Initial clinical studies for FHD-286 in relapsed/refractory AML and metastatic uveal melanoma are set to begin, with data expected by year-end 2021. Additionally, FHD-609’s IND submission is on track for Q2 2021. The company successfully raised approximately $135.2 million through an IPO and reported cash holdings of $185.8 million as of December 31, 2020, up significantly from $15 million in the previous year.
Foghorn Therapeutics (Nasdaq: FHTX) announced its participation in the AACR Annual Meeting 2021, occurring virtually from April 10-15. The company will present a poster titled ‘Discovery of novel BAF inhibitors for the treatment of transcription factor-driven cancers’, available on demand from 8:30 AM on April 10. Additionally, Foghorn will chair a panel on next-generation epigenetic drugs on April 14. Preclinical data highlight the potential of BAF ATPase inhibition, particularly for uveal melanoma, paving the way for future human studies.
Foghorn Therapeutics (Nasdaq: FHTX) announced its participation in the AACR Annual Meeting 2021, scheduled for April 10-15. The company will present a poster titled Discovery of novel BAF inhibitors for the treatment of transcription factor-driven cancers, available on demand from 8:30 AM on April 10. Furthermore, Foghorn will chair a panel discussion on Next-Generation Epigenetic Drugs on April 14, featuring an accompanying presentation on targeting the BAF complex in cancer. These initiatives align with Foghorn's focus on developing medicines targeting chromatin regulatory systems.
Foghorn Therapeutics (Nasdaq: FHTX) announced that Dr. Sam Agresta, Chief Medical Officer, will participate in a Leukemias panel discussion at the Cowen 41st Annual Healthcare Conference at 11:40 a.m. ET on March 3, 2021. The company focuses on developing innovative medicines targeting genetically determined dependencies within the chromatin regulatory system. Foghorn uses its Gene Traffic Control® platform to identify and validate potential oncology drug targets, aiming to enhance treatment options for patients.